Research group and committee session
Program at a glance
Scientific Program
Social Program
Education Course
Plenary lectures Main sympsia Research group and committee session Special and award session Corporate symposia Video on demand session Oral presentations
Plenary lectures Main sympsia Research group and committee session Special and award session Corporate symposia Video on demand session Oral presentations
| CS1 Committee of the health insurance and government relation session Pilot project of telemedicine in type 1 DM |
14:00~16:00 / Friday 18 September Channel D Chairman : Tae Sun Park, Chong Hwa Kim |
Overview |
|---|---|---|
| In this session, we would like to discuss about the progress and improvement of the “Type 1 Diabetes Telemedicine Demonstration Project,” which has been in full force since January 2020. First of all, Department of Health and Welfare Insurance Division Manager Lee Jung-Gyu will lecture on the introduction and meaning of this project, and Seoul National University School of Pediatrics and Youth Professor Kim Jae-Hyun will talk about the current status of this project and diabetes education insurance policy. After that, we’d like to have a panel discussion what to solve for a successful Type 1 Diabetes telemedicine demonstration project. | ||
|
CS1-1Introduction and signification of pilot project of telemedicine in type 1 DM | |
|
CS1-2Current status of pilot project of telemedicine in type 1 diabetes and insurance policy of diabetic education | |
|
Jae Hyeon Kim (Sungkyunkwan University, Korea) Min Jeong Gu (Seoul National University Hospital, Korea) Ji Young Kim (Seoul National University Hospital, Korea) Jum Boon Ji (HIRA, Korea) |
||
| CS2 Diabetes and metabolism journal session Special session with DMJ |
13:30~14:30 / Saturday 19 September Channel C Chairman : In-Kyung Jeong |
Overview |
|---|---|---|
| This session entitled with ‘Special session with Diabetes and metabolism journal' is designed to provide a place for clinicians and basic researchers. 'Diabetes and metabolism Journal (DMJ)’ that publish original research relevant to diabetes is the official journal of the Korean Diabetes Association indexed in SCIE, Medline, PubMed, and SCOPUS. In this session, the most outstanding articles in the DMJ in 2019 selected by The Committee of Publication of KDA will be presented with their excellent achievements. | ||
|
CS2-1Essential role of protein arginine methyltransferase 1 in pancreas development by regulating protein stability of neurogenin 3 | |
|
CS2-2Myricetin protects against high glucose-induced beta-cell apoptosis by attenuating endoplasmic reticulum stress via inactivation of cyclin-dependent kinase 5 | |
|
CS2-3Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials | |
|
CS2-4The risk of myocardial infarction and ischemic stroke according to waist circumference in 21,749,261 Korean adults: a nationwide population-based study | |
|
CS2-5PF-04620110, a potent antidiabetic agent, suppresses fatty acid-induced NLRP3 inflammasome activation in macrophages | |
|
CS2-6High proportion of adult cases and prevalence of metabolic syndrome in type 1 diabetes mellitus population in Korea: a nationwide study | |
| CS3 Diabetes prevention Efforts for the prevention of diabetes and its complications (committee of clinical practice guideline & international liaison joint session |
15:50~17:50 / Saturday 19 September Channel A |
Overview |
|---|---|---|
| Diabetes is one of the major global threats and many countries have been trying to cut down diabetes-related health burdens. This session entitled as “Efforts for the prevention of diabetes and its complications” was designed to deliver several ongoing projects to prevent diabetes epidemics as well as to integrate the diverse health records for establishing the most efficient way to combat against diabetes. This session will be a good chance to understand the current status in the field of diabetes prevention and standardization of health-related data. | ||
|
CS3-1Korean diabetes prevention study | |
|
CS3-2Japanese standard configuration for personal health records (PHR) for diabetes mellitus | |
|
CS3-3Defeating type 2 diabetes: global challenges and new solutions | |
|
CS3-4City changing project in Busan city | |
|
Seung-Hyun Ko (The Catholic University of Korea, Korea) Sung Hee Choi (Seoul National University, Korea) Kyuyeon Hur (Sungkyunkwan University, Korea) Chang Hee Jung (University of Ulsan, Korea) |
||
| RG1 ICDM-AIBIS in AASD joint symposium Islet biology |
13:30~15:30 / Saturday 19 September Channel A Chairman : Kun Ho Yoon, Ki-Ho Song |
Overview |
|---|---|---|
| This AIBIS - beta cell research group of KDA joint session is a basic session designed to provide an opportunity for clinicians and basic researchers to understand islet biology including immunity, oxidative stress, and cross-talk between organs. In this session, a variety of factors affecting beta cell function and glucose homeostasis will be discussed. Researchers will present their specific interest of islet biology area and these studies will provide in-depth knowledge related to beta cell function. | ||
|
RG1-1The mitochondrial-encoded peptide regulates CD4+ T cells and prevents autoimmune diabetes | |
|
RG1-2Defective BCAA metabolism contributes to pancreatic beta cell dysfunction in type 2 diabetes | |
|
RG1-3Stomach-pancreas crosstalk in glucose homeostasis | |
|
RG1-4Ubc9-mediated SUMOylation regulates oxidative stress and ER stress in the pancreatic β cells | |
|
RG1-5 GLP-1 agonist prevents β cells from apoptosis through improving mitochondrial function and suppressing prolonged AMPK activation | |
|
RG1-6GLP-1 receptor agonists and  -cell mass |
|
| RG2 Research group on diabetic neuropathy A new look at diabetic neuropathy |
13:30~15:30 / Saturday 19 September Channel B Chairman : Jihyun Lee |
Overview |
|---|---|---|
| This session entitled with ‘A new look at diabetic neuropathy’ is translational session and designed to provide a place for clinicians to understand the diagnosis, pathogenesis and emerging therapeutic areas for diabetic peripheral neuropathy(DPN) in people with diabetes. In this session, several novel diagnostic techniques and clinical assessment for the early detection of DPN, look at the differences between painful and painless-DPN and present strategies and emerging solutions for treating DPN, will be 3 speakers presented and 1 panelist discussed. This session will be provide the better understanding of diagnosis, pathogenesis and management of DPN. | ||
|
RG2-1New perspective in diabetic neuropathy: from the periphery to the brain | |
|
RG2-2Painful and painless diabetic neuropathies: what is the difference? | |
|
RG2-3Disease modifying therapies for diabetic neuropathy - present strategies and emerging solutions | |
|
Ie Byung Park (Gachon University, Korea) Hyuk Sang Kwon (The Catholic University of Korea, Korea) |
||
| RG3 Research group on fatty liver disease Recent updates on treatment of non-alcoholic fatty liver disease |
13:30~15:30 / Saturday 19 September Channel D Chairman : Bong-Soo Cha, Won Young Lee |
Overview |
|---|---|---|
| This session is organized by Research Group for Fatty Liver Disease. The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing globally due to the increasing prevalence of obesity and diabetes. NAFLD is a clinical feature of insulin resistance and has a reciprocal relationship with type 2 diabetes mellitues. NAFLD is considered as a hepatic manifestation of ectopic fat accumulation and metabolic syndrome. Although the pathophysiologic feature of NAFLD is well-known from the literature and research, a few treatment options are available except weight loss. In this session, we would like to review recent updates on therapeutic strategies for NAFLD and NASH. | ||
| Recent updates on treatment of non-alcoholic fatty liver disease | ||
|
RG3-1Current evidence for NAFLD treatment | |
|
RG3-2Treatment of non-alcoholic fatty liver disease with focus on non-pharmacologic option | |
|
RG3-3Treatment oF NAFLD: effect of anti-diabetic medication | |
|
RG3-4Treatment of NAFLD: non-diabetic drugs | |
| RG4 Research group on diabetic vascular cellbBiology Easy guide on how to start in vivo diabetic vascular research |
15:50~17:50 / Saturday 19 September Channel B Chairman : In-Kyu Lee, Jaetaek Kim |
Overview |
|---|---|---|
| The biggest goal of diabetes management is to prevent and treat vascular complications. In this regard, the well-designed animal study is mandatory to understand the pathogenesis of diabetic vascular complications and identify the possible therapeutic targets. In this session, we'd like to share the know-how in the field of mouse models related to the diabetic micro- and macro-vascular complications with you. | ||
|
RG4-1Simple and faster way to creat vascular cell specific KO mouse | |
|
RG4-2How to make early diabetic retinopathy mouse model | |
|
RG4-3How to make diabetic albuminuria and/or glomerulosclerosis mouse model | |
|
RG4-4Mouse models for progression and regression of atherosclerosis | |
